United Therapeutics (UTHR): +17% Surge in 30 Days on Strong IPF Trial Data
Key Takeaways
- UTHR stock surged +17% over the past 30 days, driven by positive Phase 3 TETON-1 trial results for Tyvaso in idiopathic pulmonary fibrosis (IPF), triggering a 12.5% single-day gain.
- Over the past quarter, shares rose +18%, supported by strong Q4 earnings beat, ADVANCE OUTCOMES study success for ralinepag in pulmonary arterial hypertension (PAH), and a $2 billion share repurchase authorization.
- Analyst upgrades and raised price targets from firms like TD Cowen and Cantor Fitzgerald reflect optimism around pipeline expansions and robust Tyvaso sales growth.
- Key products like Tyvaso and Orenitram continue to fuel revenue, with the company targeting a $4 billion revenue run rate by 2027.
- Positive clinical data across IPF and PAH indications positions UTHR for potential label expansions and new market opportunities.
Understanding United Therapeutics (UTHR) and Its Place in Biotech
United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.
In the competitive biotech landscape, UTHR maintains a solid position in PAH therapies with significant market share. Its approach relies on proprietary delivery methods, such as inhaled and oral treprostinil formulations, which generate reliable revenue from high-margin specialty pharmaceuticals. From what I see, the recent push to expand Tyvaso into IPF beyond PAH has aligned well with these strengths, supporting long-term growth alongside fundamentals like profit margins over 40%.
UTHR Stock Performance: 30-Day Climb vs. Quarterly Gains
In the last 30 days, UTHR stock rose +17%, moving from about $504 at the end of February to around $588. The uptrend showed volatility, capped by a 12.5% spike on March 30 after the TETON-1 data release, which built on earlier momentum from clinical updates and buyback announcements.
Over the past quarter, shares gained +18%, advancing from $497 in early January to $588. This progress included a consistent upward trajectory interrupted by key catalysts, pushing the stock to a 52-week high near $608—a sign of robust momentum in biotech.
Key Catalysts Behind UTHR's 30-Day Rise
The standout driver was the March 30 release of positive Phase 3 TETON-1 results for nebulized Tyvaso, which achieved its primary endpoint of improved forced vital capacity (FVC) by 130.1 mL in IPF patients (p<0.0001), outperforming TETON-2. This news sparked a 12.5% single-day surge on elevated volume and paves the way for an FDA supplemental application by the end of summer.
Analysts responded swiftly: TD Cowen lifted its target to $660 (Buy), Cantor Fitzgerald to $625 (Overweight), and others followed, pointing to 15-25% upside. Earlier, the March 9 announcement of a $2 billion share repurchase—including a $1.5 billion accelerated share repurchase—reinforced management confidence. I also checked this using Tickeron’s AI Screener to gauge how UTHR stacks up against industry peers. These developments drew focus to pipeline progress and shareholder returns, eclipsing minor insider sales.
Factors Fueling UTHR's Quarterly Performance
The +18% quarterly advance drew from ongoing positive momentum. It kicked off with February's Q4 earnings: EPS of $7.70 beat estimates by $0.94, while revenue hit $790 million, up 7% year-over-year despite a slight miss, propelled by Tyvaso DPI uptake.
On March 2, the ADVANCE OUTCOMES Phase 3 trial for ralinepag demonstrated a 55% reduction in clinical worsening risk for PAH patients (HR 0.45, p<0.0001), strengthening its case as an oral prostacyclin option. The $2 billion buyback provided additional lift, alongside upgrades like UBS to $705, amid institutional interest and favorable biotech sector trends in an improving macro environment. In my view, these elements underscore UTHR's edge in pulmonary treatments.
Discovering Value with Trending AI Robots
In my research process, I often turn to Tickeron’s Trending AI Robots to identify top-performing AI trading bots among hundreds on the platform. These bots analyze thousands of tickers using diverse strategies, timeframes, and metrics such as win rate, profit factor, and drawdown, highlighting the most effective ones in current markets. From short-term scalping to long-term trend following—whether momentum, mean reversion, or sector plays—they offer practical insights for refining analysis and trading approaches. One thing that stands out is how they help spot opportunities like those in biotech, and I’ve found them useful for validating trends in stocks like UTHR.
What to Watch in UTHR's Outlook
Looking ahead, key items include FDA feedback on Tyvaso’s IPF label expansion following TETON data, the full ADVANCE OUTCOMES presentation, and ralinepag’s NDA filing in the second half of 2026. Q1 earnings should shed light on Tyvaso sales momentum and progress toward the $4 billion revenue run-rate goal by 2027. I’m watching broader PAH/IPF trends, interest rate impacts on biotech valuations, and buyback progress closely. Risks involve regulatory hurdles, conference details like ATS in May, and competition, though partnerships or new data could provide upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
UTHR in +2.15% Uptrend, advancing for three consecutive days on June 24, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where UTHR advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where UTHR's RSI Oscillator exited the oversold zone, of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 51 cases where UTHR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for UTHR just turned positive on June 24, 2026. Looking at past instances where UTHR's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
UTHR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UTHR as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
UTHR moved below its 50-day moving average on May 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for UTHR crossed bearishly below the 50-day moving average on May 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for UTHR entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.871) is normal, around the industry mean (79.618). P/E Ratio (19.900) is within average values for comparable stocks, (97.708). Projected Growth (PEG Ratio) (2.205) is also within normal values, averaging (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (8.078) is also within normal values, averaging (95.237).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement